Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)

Jochen Greiner, Anita Schmitt, Krzysztof Giannopoulos, Isabel Funk, Marta Heyduk, Markus Rojewski, Jinfei Chen, Marlies Goetz, Martin Bommer, Gerd Ritter, Phillipe Guillaume, Anna Dmoszynska, Hartmut Döhner, Michael Schmitt

Blood (2008) 112 (11): 2911.

https://doi.org/10.1182/blood.V112.11.2911.2911

Published: 2008

Journal Articles

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

Blood (2008) 111 (3): 1357–1365.

https://doi.org/10.1182/blood-2007-07-099366

Published: 2008

Journal Articles

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Krzysztof Giannopoulos, MD, PhD, Andreas Buhler, MD, PhD, Jinfei Chen, MD, PhD, Alexander Krober, MD, PhD, Malgorzata Kowal, MD, PhD, Anna Dmoszynska, MD, PhD, Jacek Rolinski, MD, PhD, Jochen Greiner, MD, PhD, Hartmut Dohner, MD, PhD, Stephan Stilgenbauer, MD, PhD, Michael Schmitt, MD, PhD

Blood (2007) 110 (11): 2051.

https://doi.org/10.1182/blood.V110.11.2051.2051

Published: 2007

Journal Articles

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Jochen Greiner, MD, Anita Schmitt, MD, Krzysztof Giannopoulos, MD, Jinfei Chen, MD, Marlies Goetz, Markus Rojewski, MD, Gerd Ritter, PhD, Sascha Gnjatic, PhD, Philippe Guillaume, PhD, Mark Ringhoffer, MD, Martin Bommer, MD, Richard F. Schlenk, MD, Peter Liebisch, MD, Donald Bunjes, MD, Hiroshi Shiku, PhD, Hartmut Dohner, MD, Michael Schmitt, MD

Blood (2007) 110 (11): 1806.

https://doi.org/10.1182/blood.V110.11.1806.1806

Published: 2007

Journal Articles

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Fei Fei, MD, Yingzhe Yu, Anita Schmitt, MD, Jinfei Chen, PhD, MD, Baoan Chen, PhD, MD, Markus Rojewski, MD, Mark Ringhoffer, MD, Stefanie von Harsdorf, MD, Jochen Greiner, PhD, MD, Marlies Goetz, Philippe Guillaume, PhD, Hartmut Dohner, PhD, MD, Donald Bunjes, PhD, MD, Michael Schmitt, PhD, MD

Blood (2007) 110 (11): 2368.

https://doi.org/10.1182/blood.V110.11.2368.2368

Published: 2007

Journal Articles

RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.

Michael Schmitt, PhD, Anita Schmitt, MD, Krzysztof Giannopoulos, MD, Li Li, PhD, Peter Liebisch, MD, Jinfei Chen, MD, Mark Ringhoffer, MD, Phillipe Guillaume, PhD, Gerd Ritter, PhD, Markus Rojewski, PhD, Sascha Gnjatic, PhD, Hartmut Dohner, MD, Jochen Jochen, MD

Blood (2006) 108 (11): 409.

https://doi.org/10.1182/blood.V108.11.409.409

Published: 2006

Journal Articles

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

Jinfei Chen, MD, Anita Schmitt, MD, Baoan Chen, MD, Markus Rojewski, MD, Jochen Greiner, MD, Philippe Guillaume, PhD, Hartmut Dohner, MD, Donald Bunjes, MD, Michael Schmitt, PhD

Blood (2006) 108 (11): 2201.

https://doi.org/10.1182/blood.V108.11.2201.2201

Published: 2006

Journal Articles

RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).

Jochen Greiner, MD, Krzysztof Giannopoulos, MD, Li Li, MD, Peter Liebisch, MD, Christiane Wendl, MD, Jinfei Chen, MD, Mark Ringhoffer, MD, Phillipe Guillaume, PhD, Gerd Ritter, PhD, Hartmut Doehner, MD, Michael Schmitt, MD

Blood (2005) 106 (11): 2781.

https://doi.org/10.1182/blood.V106.11.2781.2781

Published: 2005

NARROW

High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only